Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients
Anti-PD-1 antibodies prolong survival of performance status (PS) 0–1 advanced non-small-cell lung cancer (aNSCLC) patients. Their efficacy in PS 3–4 patients is unknown. Conse- cutive PS 3–4 aNSCLC patients receiving compassionate nivolumab were accrued by 12 French thoracic oncology departments, ov...
Main Authors: | Valérie Gounant, Michael Duruisseaux, Ghassen Soussi, Sylvie Van Hulst, Olivier Bylicki, Jacques Cadranel, Marie Wislez, Jean Trédaniel, Jean-Philippe Spano, Carole Helissey, Christos Chouaid, Olivier Molinier, Xavier Dhalluin, Ludovic Doucet, José Hureaux, Aurélie Cazes, Gérard Zalcman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/5/1040 |
Similar Items
-
Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
by: Nadia Guezour, et al.
Published: (2022-08-01) -
<i>ROS-1</i> Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
by: Sébastien Gendarme, et al.
Published: (2022-01-01) -
Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
by: Jean-Baptiste Assié, et al.
Published: (2022-03-01) -
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
by: Domenico Mallardo, et al.
Published: (2023-10-01) -
Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
by: Taylor E. Woo, et al.
Published: (2023-09-01)